Pacific Edge (NZE:PEB, ASX:PEB) said the Medicare coverage for its flagship Cxbladder test has been extended by two months to Thursday, April 24, according to a Monday filing with the New Zealand and Australian bourses.
Last Jan. 22, the cancer diagnostics company disclosed plans to seek a preliminary injunction in the US relating to the removal of Cxbladder test from the coverage of Medicare contractor, Novitas.
Pacific Edge's shares were up 7% in New Zealand and 10% in Australia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。